drugset / Trial / NCT02884089

A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants

NCT02884089

Phase 1 Completed 40 enrolled Eli Lilly and Company
RandomizedCrossoverSingle-blindBasic science

Summary

This study will look at how a single dose of abemaciclib will impact the body's ability to get rid of two other drugs, metformin and iohexol. In addition, this study will evaluate the effect of a single dose of abemaciclib on kidney function by measuring blood and urine markers. Side effects will also be documented. Each participant will complete four study periods. During each study period, participants will stay in the clinical research unit for nine days and eight nights. The study will last approximately 10 weeks, not including screening. Screening is required within 28 days prior to the start of the study. This study is for research purposes only and is not intended to treat any medical condition.

Timeline

Start
2016-08
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule Oral
Subject Iohexol Diagnostic / imaging agent Intravenous
Subject Metformin Small molecule Oral

Indications

No indication recorded.